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ABSTRACT
Objective: The aim of this paper was to show that
easily interpretable maps of local and national
prescribing data, available from open sources, can be
used to demonstrate meaningful variations in
prescribing performance.
Design: The prescription dispensing data from the
National Health Service (NHS) Information Centre for
the medications metformin hydrochloride and
methylphenidate were compared with reported
incidence data for the conditions, diabetes and
attention deficit hyperactivity disorder, respectively. The
incidence data were obtained from the open source
general practitioner (GP) Quality and Outcomes
Framework. These data were mapped using the
Ordnance Survey CodePoint Open data and the data
tables stored in a PostGIS spatial database. Continuous
maps of spending per person in England were then
computed by using a smoothing algorithm and areas
whose local spending is substantially (at least fourfold)
and significantly (p<0.05) higher than the national
average are then highlighted on the maps.
Setting: NHS data with analysis of primary care
prescribing.
Population: England, UK.
Results: The spatial mapping demonstrates that
several areas in England have substantially and
significantly higher spending per person on metformin
and methyphenidate. North Kent and the Wirral have
substantially and significantly higher spending per
child on methyphenidate.
Conclusions: It is possible, using open source data,
to use statistical methods to distinguish chance
fluctuations in prescribing from genuine differences in
prescribing rates. The results can be interactively
mapped at a fine spatial resolution down to individual
GP practices in England. This process could be
automated and reported in real time. This can inform
decision-making and could enable earlier detection of
emergent phenomena.
INTRODUCTION
On 14 December 2011, the National Health
Service (NHS) Administrative Data Liaison
Service announced the free availability of
monthly prescription data by general
practitioner (GP) practice throughout
England. These data contain costing and
item counts for all prescriptions aggregated
by British National Formulary (BNF)1 code
for each GP practice or clinic. Linking the
prescription data to location, practice geode-
mographics and health statistics provides a




▪ Open source data were used to map prescribing
in primary care in England.
▪ Continuous maps of spending per person were
computed and a smoothing algorithm applied.
▪ Areas with significantly higher spending than the
national average were identified for the medica-
tions methylphenidate and metformin.
Key messages
▪ It is possible to produce easily interpretable
maps of local and national prescribing data from
open sources in England.
▪ Statistical methods can be used to distinguish
chance fluctuations in prescribing from genuine
difference.
▪ This mapping can go down a fine spatial reso-
lution and has the potential to inform decision-
making in real time.
Strengths and limitations of this study
▪ This is the first time these prescribing data have
been mapped since the National Health Service
(NHS) Information Centre made it freely available
in September 2011.
▪ This mapping has been entirely produced using
open sources of data.
▪ There is still a lag in the release of NHS data and
this restricts the current opportunities for the
early detection of emergent phenomena.
▪ This means this is currently a snapshot spatial
analysis and not a continuously updated spatio-
temporal analysis.
▪ There is currently no linkage of these data to
other data streams, such as small area census
data, but this is theoretically possible.
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To illustrate what can be done with the data, we first
look at prescription rates of metformin hydrochloride
(BNF code 060102) and compare with reported inci-
dence of diabetes from another open health data
source, the GP Quality and Outcomes Framework
(QOF) data. We then map methylphenidate prescrip-
tions (BNF code 0404000M0) and suggest that the
pattern of spatial variations in prescribing policy for
attention deficit hyperactivity disorder (ADHD) medica-




The prescription dispensing data come from the NHS
Information Centre web site (http://www.ic.nhs.uk/
services/transparency/prescribing-by-gp-practice). In this
paper we use the first month of released data, which
covers prescriptions issued in September 2011. The data
are supplied as one file with over 4 million rows in comma-
separated value format. Each row gives the practice code,
BNF code name and number, number of items dispensed,
net ingredient cost (NIC) and actual cost. In this paper we
use the NIC as our measure of the amount prescribed.
The addresses of the prescribing practices can be
downloaded from the same site as the prescription data.
This is another comma-separated value file with about
10 000 rows. The file gives the name and address of each
practice together with the NHS practice code that links
it to the prescription dispensing data file.
These two data sets are released under the Open
Government license (http://www.nationalarchives.
gov.uk/doc/open-government-licence).
The demographics of English GP practices can be
downloaded from another Information Centre web site
(https://indicators.ic.nhs.uk/webview), in the section on
GP practice data. The site states: ‘Copyright 2011 The
NHS Information Centre (General and Personal Medical
Services Statistics)’ but no exact license or usage require-
ments are obvious. The most recent data are for August
2010, and so we used these. Each practice record has the
total number of registered people, a breakdown of that
number into six age categories and a further division of
those age categories into male and female numbers.
These data include the same practice code as used in the
prescription address data. However, linking these
together only matches 8221 records because the remain-
der of the 10 000 or so prescription address data records
are places such as specialist clinics, hospitals and
out-of-hours services that do not have a registration
system. Visual inspection of the non-matching records
confirms this from the names of the unmatched records.
A dataset of postcodes with OSGB grid reference coordi-
nates is available from the Ordnance Survey in their
‘CodePoint Open’ product (http://www.ordnancesurvey.
co.uk/oswebsite/products/code-point-open). The license
states that it is free to view, download and use under OS
OpenData terms. This data matches the postcodes in the
prescribing address file once the postcodes in that file
have had spaces removed. For example, the code LA1 4YF
appears in the Ordnance Survey data as LA14YF, with no
spaces.
The data tables were stored in a PostGIS (http://www.
postgis.org) spatial database for retrieval by GIS and
statistical packages. An illustration of the database struc-
ture appears in figure 1.
Smoothing the data
The data are based on point locations but we would like
to produce continuous maps of spending per person
over England. We use a smoothing algorithm whereby
the value at some arbitrary location is the distance-
weighted average of the spending per person at enough
practices in the vicinity of that location to constitute a
population of a given fixed size. We then compute this
over all points on a grid over the land surface of
England. SEs of the smoothed surface can also be com-
puted (see online supplementary appendix).
The effect of this smoothing algorithm is similar to an
adaptive-bandwidth kernel smoothing. In areas with a
high density of practices, such as in a city, the gridded
values only depend on practices within a small neigh-
bourhood. In a sparse region the algorithm has to
search over longer distances to find enough practices.
The choice of population size can be made by minimis-
ing a statistical criterion such as cross-validated mean
squared error, or be chosen pragmatically, for example,
as a constant times the average registration size of a GP
Figure 1 Database structure.
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practice. We can also use the age and sex stratification of
the GP list data to define a baseline population in a spe-
cific age and/or sex stratum of the population.
From our smoothed estimates and SEs we can map
areas that are excessively high or low, where ‘excessively’
can be chosen as some multiple or fraction of the
country-wide average rate. For example, using the values
of 4 and 0.25, our maps show the one-sided p values
for tests of the null hypotheses that the local rate is at
most four times or at least a quarter of, respectively,
the country-wide average. Areas with p values below the
critical 0.05 level are then highlighted in red for high
values and blue for low values.
RESULTS
Diabetes
The QOF is an annual reward and incentive programme
for all GP surgeries in England, which details practice
achievement results (http://www.qof.ic.nhs.uk). In 2010/
2011, QOF measured achievement against 134 indicators.
The NHS Information Centre has made the information
freely available and this provides easy access to comprehen-
sive information on the pattern of chronic disease across
over 54 million registered patients in England. These out-
comes include the prevalence within practices for diabetes
and are available for download from the NHS Information
Centre website (https://indicators.ic.nhs.uk/webview).
Table 1 Item count and net ingredient cost (NIC) for
metformin preparations
Name Item count NIC













Figure 2 Smoothed metformin spending (net ingredient cost per person) over the whole of England.
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The figures are published annually. For this study we use
the data from October 2011. The practice code is
included, so we can use the addresses and postcode tables
described earlier to map point prevalence diabetes at
approximate GP practice locations.
Metformin is recommended by the National Institute
for Health and Clinical Excellence (NICE) as first-line
treatment in obese individuals diagnosed with type 2 dia-
betes2 and appears in the database with BNF codes start-
ing with 060102. This includes combination
prescriptions with thiazolidinediones and other drugs.
Table 1 shows the total item count and NIC spent on
these drugs in the data. Because 99.8% of the prescrip-
tions are for metformin hydrochloride on its own, we
will use the total cost of that specific BNF code item
(0601022B0). As a denominator for the population for
each practice we use the total number of people regis-
tered from the demographic data.
Investigation of the database shows only a relatively
small amount of spending on metformin products from
clinics without practice lists, not enough to materially
affect the conclusions given here. Where two or more
practice locations have the same post-code, we sum the
spend and practice populations and compute a spend
per person based on all the practices at that postcode.
Similarly, for the prevalence outcome measure we can
compute an overall prevalence at a location since the
data contain the raw numerator and denominator values
as well as the computed prevalence.
Figure 2 shows the spending per person smoothed over
England using the previously described smoothing algo-
rithm, overlaid on OpenStreetMap base data (http://www.
openstreetmap.org). A population size of 100 000 was
used to compute the weighted averages at each grid point.
One outlying practice was found with more than 50 times
the maximum spend per person of any other practice and
was removed from the data.
As an initial comparison of the spending data and the
prevalence values we can plot point maps of the practice
locations coloured according to the value. Figure 3
shows two areas, Sheffield and London, with the points
coloured by categorising the points into five quintiles.
The highest fifth of all points are coloured bright red,
the lowest fifth are bright blue. The intermediate quin-
tiles are coloured dull red, grey and dull blue. This
serves to highlight the extreme values. Inspection of the
Figure 3 Diabetes prevalence (left) and metformin spending (net ingredient cost per person, right) in Sheffield (top) and London
(bottom). Points are colour coded by quintiles: from bright blue (lowest), through dull blue, grey, dull red and bright red (highest).
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maps in a desktop mapping package, Quantum GIS
(http://www.qgis.org) showed the expected correspond-
ence of both measures over the whole country.
Figure 4 is a scatterplot of the metformin cost per
person against the prevalence for the 8111 GP practices.
To improve the clarity of the plot, 20 outlying points
(with cost per-person values between £0.50 and £2.50)
have been excluded. The correlation coefficient for this
scatterplot is 0.49.
We can use the quintile classification used for colouring
the map points to get another assessment of how well the
metformin spending correlates with the reported preva-
lence. We compute a table of the difference in quintile
classification for each GP practice where we have both
measures. This tells us how many quintiles are exactly the
same, and how many are one, two, three or four categories
different in each direction. In table 2, we show the
number (out of 8111) of practices in each category and
the corresponding proportion.
Table 2 shows that about 80% of the practices are in
either the same or adjacent quintile categories. Note
that the four left-most columns of table 2 come from
practices where the quintile of the cost from the dispens-
ing database is less than the quintile from the QOF
prevalence report, while the four right-most columns are
where dispensing cost is in a higher quintile than the
prevalence quintile.
ADHD and methylphenidate
Methylphenidate is licensed in the UK for the treatment
of ADHD and is also recommended by NICE.3 Treatment
with methylphenidate is usually initiated by specialists
Figure 4 Metformin spending (net ingredient cost per person) against prevalence for the 8111 general practitioner practices
in England.
Table 2 Table of net ingredient cost (NIC) quintile minus prevalence quintile
Difference –4 –3 –2 –1 0 1 2 3 4
Number 29 209 663 1628 3193 1456 648 217 68
Proportion 0.004 0.026 0.082 0.201 0.394 0.180 0.080 0.027 0.008
Positive (negative) differences correspond to practices whose NIC falls in a higher (lower) quintile than their reported prevalence.
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with ongoing prescriptions on a shared-care basis with
general practice. Prescriptions of methylphenidate
appear in the database with the BNF code of 0404000M0.
This combines standard-release non-proprietary and pro-
prietary (Ritalin) medication as well as more expensive
modified-release versions.
The total spending in England is just under £2 million
on a total GP-registered population of 55 million adults
(£0.035 per person) or 10 million children (£0.20 per
under-14). Figure 5 is a map of smoothed methylphenid-
ate spend per child, using an included population of
10 000 children aged 14 or below in the smoothing algo-
rithm. The map is coloured so that grey is the national
average, while blue and red are below and above the
national average, respectively.
This map shows a few high spots, the highest being in
north Kent. Figure 6 shows areas significantly above four
times the national average in red. The area in north
Kent is above this threshold, as is a small area on the
Wirral peninsula, and a tiny area in Norwich. Nowhere
on the map is significantly below one-quarter of the
national average rate.
It is possible that substantial spending on methylphenid-
ate comes from specialist clinics rather than GPs with a
registered list. Without a measure of the size of these
clinics we cannot work out how many children are being
served. However, we can aggregate spending from all
sources within regions and compare across regions.
Table 3 shows the top 10 spending locations for practices
with and without registered lists. This shows that we cannot
neglect the spending from the clinics in any assessment of
the geographic spending pattern. In each part of figure 7
we show points coloured by methylphenidate spending
per child on each GP register. Overlaid on each map are
some ad hoc regions within which we can find the total
spend from both GP practices with registration lists and
from clinics without registers. As a denominator we can
take the total number of children or people registered to
GPs in those regions, and then produce the spend per
child or per person within each region.
Figure 5 Smoothed methylphenidate spending (net ingredient cost per child) over the whole of England.
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As well as comparing parts of Kent and parts of
Merseyside, where the two most extreme prescribing
rates are locates, we examine divisions of the two most
populated areas of England, namely London and the
West Midlands. A visual inspection of the West Midlands
shows some increased spending in the western area, but
London does not show any comparably simple geo-
graphical trend. The table of spending computed from
all GP and non-GP sources for these regions will show if
those non-GP sources make a substantial contribution to
Figure 6 Areas whose smoothed methylphenidate spending (net ingredient cost per child) is significantly above four times the
national average (p=0.05).
Table 3 Top 10 methylphenidate dispensers by net ingredient cost (NIC), with and without a register
Sources with a register (mostly general practices) Sources without a register (mostly clinics)
NIC (£) Location NIC (£) Location
3671.96 The OM Medical Centre, Kent 7929.60 The Child Health Unit, Essex
3456.41 St. Georges Medical Centre, Kent 4398.76 Community Paediatricians, Coventry
3233.68 Wensum Valley Medical Practice, Norfolk 3437.39 CAMHS Gulson Clinic, London
2762.95 Vida Healthcare, Norfolk 3379.84 CAMHS, Chesterfield
2640.42 Coastal Medical Group, Lewes 3020.84 CAMHS Whitestone Clinic, Warwickshire
2598.96 Dr Wilczynski & Partners, Northamptonshire 2814.99 CAMHS, West Lancashire
2547.77 The Chestnuts Surgery, Kent 2445.07 Children’s Centre, Middlesex
2430.84 Mantgani AB & Partners, Wirral 2229.33 Community Paediatricians, Worcestershire
2415.55 Woodlands Family Practice, Kent 2060.11 CAMHS, Worcester, Worcestershire
2342.61 St. James Medical Practice, Norfolk 1752.52 Drug Clinic (Sch), Birkenhead
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overall spending here. Table 4 shows the spending per
child and per person in those regions as well as the
England-wide average. The highly increased spending in
North Kent and the Wirral is still evident compared with
nearby regions, even with the added non-GP spending.
A preliminary analysis of the October 2011 data shows
similar behaviour to the September 2011 data.
DISCUSSION
We have shown that the newly released data can be used
to produce maps of prescribing data across England.
These maps can reveal geographical variations in pre-
scribing patterns that are not immediately apparent and
may be clinically significant. Spatial analysis has been
used in Taiwan to demonstrate the heterogeneity of car-
diovascular drug prescribing but this was at a coarser
spatial resolution (over 352 townships).4 It also focused
on testing for departure from spatial homogeneity of
prescribing rates, rather than on estimation of relative
rates, but it was able to pick up a clear disparity between
northern and southern regions. An analysis in the USA
looked at geographic variation in prescribing decisions
in diabetes.5 It was conducted at the level of hospital
Table 4 Regional methylphenidate spending (net
ingredient cost, NIC) per child and per person, by region
Region Per child (£) Per person (£)
North Kent 0.724 0.133
South Kent 0.322 0.157
East Kent 0.118 0.020
Wirral 0.604 0.099
Liverpool 0.074 0.012
West Midlands (West) 0.304 0.054
West Midlands (East) 0.074 0.015
London (North) 0.117 0.021
London (South) 0.170 0.030
England average 0.207 0.035
Figure 7 Methylphenidate spending (net ingredient cost per child) in selected regions. Points are colour coded by quintiles:
from bright blue (lowest), through dull blue, grey, dull red and bright red (highest).
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referral region (n=306) and used regression models to
investigate the relationships between prescribing rates
and sociodemographic risk factors such as ethnicity,
gender and income.
The strength of this analysis is that it shows how a stat-
istical method can be used to distinguish chance fluctua-
tions from genuine differences in prescribing rates.
Interactive mapping of the results can be accomplished
and analysis can be automated, hence conducted and
reported in real-time. The data from this analysis are
comprehensive, and at fine (individual GP practice-
level) spatial resolution across all of England.
The major limitations of the data are that they are only
available at a monthly time resolution and that there is an
11-week time-lag in the release of the data. The results
presented here can therefore only provide a snap-shot
spatial analysis rather than a continuously updated spatio-
temporal analysis. There is no automatic linkage to other
relevant data-streams, for example, NHS111 or small-area
census data, but linkage to these is straightforward in
principle.
Methyphenidate is not the only medication that can
be used for ADHD. NICE have suggested atomoxetine
and dexamfetamine are options medical professionals
may wish to consider in more complex cases.
Methylphenidate is prescribed much more frequently
than the other recommended medications for ADHD.
Our initial investigations showed that the data for ato-
moxetine and dexamfetamine are dominated by GPs
with zero prescriptions. Preliminary investigation at the
regions of interest shows some spatial patterns that
match those for methyphenidate; but the small numbers
make formal analysis problematic. In addition, methyl-
phenidate may also be used in other conditions and it is
an unlicensed treatment option in narcolepsy. It is not
possible to match diagnoses to medications in these
datasets and this should be recognised as a limitation in
the interpretation of the results.
There are some limitations in the GP patient age break-
down with groups being split into ages 0–4 and 5–14. We
have mapped these two groups together. While methyl-
phenidate does not have a license for use in children
under age 6 it is still used. The data provide a good
approximation of a young population but we are limited
by the age categories and they do not provide information
on prescribing in older adolescents and adulthood.
Data relating to all aspects of healthcare systems are now
routinely collected and stored electronically, but
all-too-rarely analysed. This represents a lost opportunity
because in any complex system, continuous monitoring of
performance is key to process improvement.6 Analysing
health-related outcomes in real time can provide early
identification of anomalies in the overall pattern of vari-
ation while distinguishing between chance fluctuations
and genuine differences in system performance. This, in
turn, can inform decision-making, either to allocate
resources in order to deal with an acute problem, or to
address systemic weaknesses.
Our results show how modern statistical methods can
be used to convert spatially resolved prescribing data
into easily interpretable maps of local and national varia-
tions in the underlying prescribing rates of individual
prescription items or groups of clinically related items.
Often, statistically significant variations in prescribing
rates can be at least partly explained by geographical var-
iations in known risk factors for particular conditions.
The simple smoothing method described here can then
be extended to a semiparametric regression model7 that
decomposes the observed prescribing rate at any loca-
tion into a multiple regression term with the known risk
factors as covariates, a term for unexplained spatial vari-
ation that may warrant further investigation, and a spa-
tially unstructured residual.
The government is to be congratulated for making pub-
licly available the data required for this analysis. The value
of the data would, however, be greatly increased if future
releases could be made more frequently and more quickly.
The current frequency is monthly, while the data relating
to September 2011 were released almost 11 weeks later, on
14 December. Increasing the frequency from monthly to
weekly, and reducing the delay between the end of each
reporting period and the release of the corresponding
data, would enable earlier detection of emergent phenom-
ena, such as localised outbreaks of food-borne disease or
seasonal influenza epidemics.
A single week’s data might be too sparse in themselves
to detect more than the most obvious variations in
underlying prescribing rates. However, the same statis-
tical modelling principles that we have used here to
smooth out chance geographical variations in prescrib-
ing rates by discounting spatially referenced information
according to increasing distance from the location of
interest could be applied to smooth out chance tem-
poral variations by discounting past information accord-
ing to its age. In some contexts, a further increase in
frequency to daily releases would be even better; we
have previously demonstrated this in using daily records
of calls to NHS Direct for real-time syndromic surveil-
lance.8 9 In the current context, the natural rhythms of
the working week make it harder to argue that daily
reporting of prescription rates would generally be any
more informative of the incidence or prevalence of
related health conditions than would weekly reporting.
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